Xpovio combo plus mezigdomide to be tested in relapsed-refractory MM
A Phase 1/2 clinical trial will evaluate the safety and efficacy oral mezigdomide, Bristol-Myers Squibb’s investigational treatment, when added to the approved oral…
A Phase 1/2 clinical trial will evaluate the safety and efficacy oral mezigdomide, Bristol-Myers Squibb’s investigational treatment, when added to the approved oral…
A cell-based vaccine designed to promote immune responses against survivin, a protein that helps tumor cells survive and expand, was found to be safe and…
The U.S. Food and Drug Administration (FDA) has granted conditional approval to Pfizer‘s elranatamab — an antibody therapy to be marketed under the brand…
A European Medicines Agency committee has recommended that one antibody-based cancer therapy from Janssen Pharmaceuticals be approved for the treatment of relapsed and refractory…
The International Myeloma Foundation (IMF) will host its second in-person Patient and Family Seminar of the year on Aug. 18-19 in Los Angeles.
Janssen is asking the U.S. Food and Drug Administration (FDA) to expand approval its cell therapy Carvykti (ciltacabtagene autoleucel) to allow for earlier…
ISB 1442, Ichnos Sciences’Â investigational bi-specific antibody-based treatment, has earned orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or…
Multiple myeloma patients in the U.S. will now have access to Rapid Novor‘s noninvasive and highly sensitive blood test for monitoring minimal residual…
The U.S. Food and Drug Administration (FDA) has granted fast track and regenerative medicine advanced therapy designations to CT103A, IASO Biotherapeutics’ experimental CAR T-cell therapy…
Extremes in body mass index (BMI) — a ratio of weight to height that’s used to estimate a person’s healthy weight — are associated with…